TrialESMO open2022

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.

V Boni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.